We studied 34 patients undergoing elective repair of an abdominal aortic aneurysm under combined general anaesthesia and epidural block to evaluate the acute effects of diaspirin crosslinked haemoglobin (DCLHb) 50, 100 and 200 mg kg -1 i.v. Haemodynamic variables were measured continuously using pulmonary and radial artery catheters, and oxygen delivery and consumption were calculated at regular intervals. DCLHb was shown to be vasoactive, producing an increase in mean arterial pressure of approximately 25% with each dose, with small decreases in cardiac index and calculated oxygen delivery. These effects persisted beyond the end of infusion and provided a degree of cardiovascular stability during the operative procedure. The effects of DCLHb on oxygen consumption at these doses were minimal. 1999; 83: 702-7 
Healthcare Corporation, Deerfield, IL, USA) was developed We studied 34 patients after obtaining written informed originally as a 'blood substitute'. It consists of stroma-free consent and approval from the Lothian Health Anaesthetic human haemoglobin derived from unused but fully screened and Dentistry Research Ethics Sub-committee. All patients and tested blood donations. The haemoglobin is crosslinked were undergoing elective repair of an infrarenal aneurysm at a specific site between the alpha subunits with bis(3,5-of the abdominal aorta. Patients with occlusive aortic disease dibromosalicyl) fumarate (DBBF) to prevent dissociation were excluded. A detailed assessment of fitness for surgery of the haemoglobin molecule into dimers. The intravascular (which included evaluation of exercise tolerance, ECG, chest half-life of the stabilized tetramer is thereby increased and radiograph, pulmonary function tests and radionucleotide oxygen binding affinity is decreased, theoretically improving ventriculogram) was made approximately 1 week before oxygen delivery to tissues. The crosslinked tetramer is of hospital admission. One day before surgery, patient height, such stability that it can be pasteurized at high temperature to weight and ASA status were noted, and full blood count, inactivate viruses and precipitate uncrosslinked proteins. 1 2 urea, electrolytes and liver function tests were measured. Ultrafiltration is used to remove viral particles and precipitThis was a single-blind, randomized, dose-incremental ated proteins. [2] [3] [4] study. When the recruitment process was complete, ranIn this study, we have evaluated the effects of low doses domization was performed by the hospital pharmacy departof DCLHb in anaesthetized patients undergoing elective ment. Patients were assigned to either an active (DCLHb) repair of abdominal aortic aneurysm. Patients undergoing or control (Ringer's lactate) group. Doses of DCLHb were this procedure were chosen for the study because they have 50 mg kg -1 (group A), 100 mg kg -1 (group B) and invasive monitoring and are potentially haemodynamically 200 mg kg -1 (group C), corresponding to 35, 70 and 140 ml unstable. The study was part of a larger, multicentre study in a 70-kg patient, respectively. Control patients received involving 70 patients undergoing elective abdominal aortic the equivalent volume of Ringer's lactate. The maximum repair at three European hospitals. We describe the haemo-volume of fluid administered to any patient was 160 ml. dynamic findings of aortic aneurysm patients enrolled at One of two consultant anaesthetists and one of three consultant surgeons performed anaesthesia and surgery, the Royal Infirmary, Edinburgh only.
respectively. Standard premedication, including morphine verified by thermodilution at specific times. Data that could not be verified by thermodilution were excluded (hence the 5 or 10 mg i.m. and oral temazepam 10 or 20 mg in patients less than and more than 50 kg, respectively, was given at non-availability of data relating to cardiac output at 15 min after infusion). V O 2 and DO 2 data were not calculated at 06:00 on the day of surgery. All patients had peripheral venous and radial arterial cannulae and a mid-thoracic 15 min after infusion because of the logistics of collecting arterial and mixed venous samples at commencement of epidural catheter inserted under local anaesthesia before induction of general anaesthesia. A test dose of either 2% surgery.
Times of specific surgical events were also recorded (to lidocaine 5 ml (groups A and B) or 0.5% bupivacaine 5 ml (group C) was injected epidurally while the patient was allow subsequent grouped analysis), as were amounts of blood, blood products, fluids and drugs administered during awake. Anaesthesia was induced with thiopental 125-500 mg i.v. and maintained with 1-2% enflurane and 65% and after operation.
All patients received a minimum of 1 litre of crystalloid nitrous oxide in oxygen. Neuromuscular block was achieved with vecuronium 5-10 mg (with increments of 1-2 mg) to (Ringer's lactate) followed by 1 litre of colloid (Gelofusine) after administration of the study solution. When further facilitate tracheal intubation and lung ventilation. End-tidal carbon dioxide partial pressure was maintained at 4.5-fluid was required during surgery, crystalloid (either Ringer's lactate or 0.9% saline) or blood was given (at the 5.5 kPa.
The ECG, intra-arterial pressure and arterial oxygen discretion of the anaesthetist) to maintain PAOP within 3 mm Hg of baseline values. No further artificial colloid saturation were monitored continuously. A triple-lumen pulmonary artery catheter (Baxter Edwards Vigilance, was used and blood was administered when it was estimated that packed cell volume had decreased to Ͻ25%. A standard Irvine, CA, USA) was inserted after induction of anaesthesia to allow continuous monitoring of central venous pressure regimen for administration of fluid and vasopressor drugs was followed. Hypotension was defined as a decrease in (CVP), pulmonary artery pressure (PAP) and cardiac output. The latter was checked intermittently by bolus thermodilu-MAP of ജ30%, despite a PAOP of Ͼ10 mm Hg, and was treated with ephedrine if heart rate was Ͻ70 beat min -1 or tion. Positioning of the pulmonary catheter was verified by chest x-ray. Pulmonary artery occlusion pressure (PAOP) methoxamine if it was ജ70 beat min -1 . The amount of ephedrine and methoxamine used, and the frequency at was measured before each cardiac output calculation. When cardiovascularly stable (5 min minimum), baseline record-which they were given, were used as measures of cardiovascular stability. After surgery, patients were transferred ings of heart rate, mean arterial pressure (MAP), mean pulmonary artery pressure (MPAP), PAOP, CVP and cardiac to the high dependency unit (HDU) or intensive care unit (ICU) and time spent in each unit was recorded, together output were made. In addition, simultaneous blood samples were obtained from the arterial and pulmonary artery with duration of hospital stay.
Haemodynamic data are those collected over the first 6 h catheters for immediate measurement of arterial and mixed venous oxygen saturation and content by co-oximeter after infusion. Values were retrieved from the computer record and verified by written notes at the specified time (Instrumentation Laboratories, IL3, Lexington, MA, USA) to allow calculation of oxygen consumption (V O 2 ) and intervals so that they could be reported directly or used for calculation of cardiac index (CI), systemic vascular delivery (DO 2 ), according to the following equations: resistance index (SVRI), DO 2 and V O 2 . Values were indexed DO 2 ϭ(cardiac indexϫarterial oxygen content)ϫ10
to allow for variations in patient body size and weight.
Statistical analyses were performed using SAS (version venous-arterial oxygen difference)ϫ10 6.07) (SAS Institute Inc., Cary, NC, USA). Data were analysed by the method of mixed models, using residual When the initial data set was complete, DCLHb or control solution was administered via an infusion pump (Imed, maximum analysis to estimate variance components. 5 The dose incremental design required the use of a 'nested Advanced Medical Inc, San Diego, CA, USA) over 15 min into a central (group A) or peripheral (groups B and C) model', with each active treatment group being considered as a sub-study. An overall test of due difference between vein. After completion of the infusion, an epidural top-up dose of 0.5% bupivacaine was given and surgery com-control and active conditions was made and, in addition, this comparison was made separately within each sub-study. menced. Haemodynamic data (heart rate, cardiac output, MAP, CVP and MPAP) were recorded continuously for 7 h Interactions between condition, dose and time were also tested. Two-tailed tests were used with Pഛ0.05 being after the beginning of infusion. Where possible, haemodynamic measurements were made for 24 h after operation. considered significant. Comparisons of fluid input and output, and dose and frequency of vasoconstrictor adminisHeart rate and all arterial pressures were measured every 3 min; for cardiac output, the Vigilance provided updated tration were made using the Student's t test. Because of the small sample size, statistical significance at individual times averaged values every 6 min. A Dual 486 notebook computer was interfaced with the patient monitoring system (Hewlett-could not often be demonstrated. P values refer to the overall difference between active and control conditions Packard Merlin, Andover, MA, USA) using an RS232 link to collect all data. Measurements of cardiac output were (combined data set). 
Results
The majority of the 34 patients enrolled at this site were male and elderly; all were Caucasian and 40% had a history of essential hypertension (Table 1 ). There were minimal differences in patient characteristics between the sub-groups. Two patients were excluded because they did not undergo aortic aneurysm repair. One had aneurysm repair abandoned because of previous adhesions, preventing surgical access; laparotomy and repair of perforated bowel were performed. The other patient was found to have an extension of his aneurysm into the thorax, which prevented surgery as planned, and his results were excluded from analysis. There were no differences between groups in the time spent in the HDU, ICU or in hospital. There were no deaths reported during the study or at a 4-month follow-up visit.
Major cardiovascular effects
Before infusion, there were no significant differences in cardiovascular variables between groups. In group A, baseline MAP was 66.2 (SEM 6.4) mm Hg in the control group and 79.6 (4.4) mm Hg in the DCLHb group; in group B, MAP was 80 (4.6) in the control group and 73 (2.8) mm Hg in the DCLHb group; and in group C, MAP was 88 (6.9) mm Hg in the control group and 76 (5.7) mm Hg in the DCLHb group. After DCLHb infusion, MAP increased significantly in all three groups from baseline values (Fig. 1) . This effect was consistent, immediate and persisted well beyond the end of infusion. There was no significant decrease in heart rate corresponding with the increase in MAP.
After infusion of DCLHb, SVRI increased significantly Heart rate for DCLHb at these small doses (Fig. 2) . It persisted for 2 h in patients receiving dose B and for 6 h in those Heart rate did not change throughout the study in control patients or with any of the doses of DCLHb. Mean heart receiving dose C.
The effects of DCLHb on CVP and SVRI are not reported rate at the start of infusion in group A was 63 (SEM 4) and 61 (4) beat min -1 for control and treated patients, for group A as some patients received the study solution centrally and others did not. When using the central venous respectively, in group B, 62 (7) and 63 (4) beat min -1 and in group C, 77 (6) and 67 (8) beat min -1 , respectively. route, we noted that the use of the infusion pump caused an artificial increase in CVP. From Dose B onwards, all Mean heart rate for all three groups did not decrease to less than 56 or increase to more than 83 beat min -1 throughout delivery of oxygen by 30% to 555 (SEM 28) ml min -1 within 30 min of commencement of infusion in those patients the study. There were no significant differences in heart rate between the DCLHb and control groups for any of treated with DCLHb 100 mg kg -1 (Pϭ0.002). This effect lasted for 2 h. Oxygen delivery never decreased to critical the doses. levels during this time. The lowest absolute level of oxygen
Other cardiovascular variables
delivery was 336 ml min -1 which occurred in one patient 2 h after administration of DCLHb 100 mg kg -1 . A summary of the data for MPAP, CVP and CI is given in Table 2 . Recordings of these variables were made at the
Other measured variables
same times indicated in Figure 2 , but limitation of space prevented full publication of every value. There were no There were no significant or clinically notable differences significant changes in any of these variables at individual between control and treatment groups in blood loss during times. When the variables were analysed statistically over operation or in the total volume or type of i.v. fluids given. time, there were no significant differences between groups. On the day of operation, control patients lost an average of 3016 (range 1025-4696) ml of blood and received 8005
Oxygen delivery and consumption (5485-9792) ml of i.v. fluids. The equivalent values for DCLHb patients were 2720 (1180-4557) ml and 8458 Table 2 also shows values for oxygen delivery and consumption. Delivery and consumption are reported only for doses (5698-14013) ml, respectively. More than 50% of patients required blood transfusions. B and C because of problems with sample handling leading to errors in oxygen content calculation at the 50 mg kg -1 dose.
All patients received vasopressor agents during anaesthesia and surgery, but fewer administrations and lower cumuThese problems were overcome with the two higher doses.
The only significant change was a decrease in mean lative doses of both ephedrine (Pϭ0.023) and methoxamine Table 3 Use of vasoconstrictor drugs from the start of infusion to the end of surgery. Intervention refers to each time that the anaesthetist gave a drug to increase arterial pressure during surgery and up to 6 h after surgery (Pϭ0.045) were required in patients who received DCLHb increases in CVP or MPAP make it unlikely that a reduction compared with those in the control group (Table 3) . in myocardial performance was the cause of compensatory vasoconstriction. In addition, a study observing the effect of DCLHb in patients after cardiopulmonary bypass did not Discussion demonstrate any myocardial depressant effect. 13 Our intention was to observe the vasoactive properties of Decreases in calculated DO 2 were associated with changes low-dose DCLHb in a human population. A single-blind in cardiac index. When the effect of DCLHb was analysed design was used because of the distinctive red colour of by dose (100 and 200 mg kg -1 only), calculated global DCLHb. Ringer's lactate cannot be altered to mimic this DO 2 decreased significantly only in patients who received colour. The history of adverse events associated with other DCLHb 100 mg kg -1 (Pϭ0.002). The value of 555 (28) haemoglobin solutions 6 7 led to the view that an early clinical ml min -1 was the lowest mean oxygen delivery recorded study should be open in design and involve progressive which occurred at 30 min after DCLHb 100 mg kg -1 . dose increments. The two lower doses used (50 and
The lowest absolute oxygen delivery in any patient was 100 mg kg -1 ) had already been evaluated in young healthy 336 ml min -1 . This was not clinically significant. It must volunteers. 8 The higher dose was felt to be a reasonable be remembered that these patients were anaesthetized and progression in the absence of adverse events at the two as such did not have a high demand for oxygen. Oxygen lower doses.
delivery being depressed to supply dependent consumption In our study, MAP and SVRI increased with all DCLHb levels was therefore not demonstrated at these doses of doses and smaller amounts of vasopressor drugs were used DCLHb. Also, the smaller size and lower viscosity of in patients who had received DCLHb. In the absence of an DCLHb allows rapid administration and it is possible to increase in cardiac output, the primary cause of the increase speculate that it may deliver oxygen to poorly perfused in arterial pressure appeared to be related to peripheral tissues, improving the status of the microcirculation despite vasoconstriction. Several mechanisms could explain this: reduction in cardiac index and global oxygen delivery. 14 DCLHb, in common with free intravascular haemoglobin, DCLHb has been developed as an adjunct to resuscitation is thought to scavenge intravascular nitric oxide. It may of patients suffering from haemorrhagic shock. The vasoaffect directly vascular smooth muscle by interacting with active properties of DCLHb have been studied and characteradrenoreceptors or it may stimulate endothelin release or ized in several animal models 9 15-17 and demonstrated in up-regulation of endothelin receptors. 9-12 The increase in humans. 8 18-20 Results of animal work suggested that arterial pressure after infusion of DCLHb was associated DCLHb may have potential use as a resuscitation fluid. 21-23 with a clinically notable but not statistically significant Unfortunately, the results of two, unpublished, controlled reduction in cardiac index which, in part, may be caused studies of the use of DCLHb in patients with haemorrhagic by increasing afterload associated with the vasoactive shock in Europe and the USA have proved disappointing. properties of DCLHb. This was not simply a result of a Baxter Healthcare have since stopped manufacturing this few outlying values as reductions in cardiac index were solution but haemoglobin solutions with similar properties noted in almost all patients receiving DCLHb. The outcome to DCLHb may well be developed in the future. from surgery was universally good with no deaths and no At a dose of DCLHb 200 mg kg -1 , DO 2 was depressed excess morbidity or evidence of malperfusion in DCLHb but not significantly, and we speculate that this may have patients. Therefore, we conclude that depression of cardiac been because the total haemoglobin content of blood was output and possible increased cardiac work was benign.
increased sufficiently to have compensated for decreased The common use of drugs to increase afterload, such as cardiac output. This may also explain the apparent boost in methoxamine, almost certainly has a similar effect and yet oxygen delivery at 60 min after the start of DCLHb clinical practice allows for the use of such agents without undue concern. The absence of clinically significant 200 mg kg -1 . DCLHb which has also been noted in a study in critically 13 Baron JF, Berridge J, Brichant JF. On behalf of the DCLHb Cardiac Surgery Trial Collaborative Group. A randomized trial to assess ill patients. 20 The doses used in the DCLHb group suggest the efficacy of diaspirin crosslinked hemoglobin (DCLHb) solution a useful clinical effect, but the single-blinded nature and as an alternative to blood transfusion following cardiac surgery.
small size of our study must be taken into account. 
